To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Pregabalin Open-Label, Multicenter Add-On Trial Following a 4-Day Double-Blind Transition Period to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00141245

Enrollment

325

Registered

2005-09-01

Start date

1998-10-31

Completion date

2005-11-30

Last updated

2007-01-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seizure Disorder, Partial

Brief summary

To evaluate long-term safety and efficacy of pregabalin in patients with partial seizures.

Interventions

DRUGPregabalin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Must have met the inclusion criteria for preceding double-blind study * Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion criteria

* Cannot have absence seizures

Design outcomes

Primary

Measure	Time frame
Safety Efficacy	—

Countries

Australia, Austria, Belgium, Finland, France, Germany, Italy, Netherlands, South Africa, Spain, Sweden, Switzerland, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026